Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018

Publication ID: GMD0318113
Publication Date: March 20, 2018
Pages: 53
Publisher: Global Markets Direct
Region: Global

$3,500.00

Publication License Type *
- Single User License (PDF), $3,500.00
- Site License (PDF), $7,000.00
- Global License (PDF), $10,500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Description:
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018

Summary
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. The latest report Collagenase 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Toxicology, Central Nervous System, Infectious Disease and Respiratory which include indications Osteoarthritis, Chemotherapy Induced Peripheral Neuropathy, Allergic Asthma, Alphavirus Infections, Arthralgia, Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.

Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents:
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Takeda Pharmaceutical Co Ltd
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZF-198 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZF-760 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Mar 01, 2018: Paradigm Reports Osteoarthritis Pain Reduced by 50%
Jan 24, 2018: Current and past elite sportspeople successfully treated with PPS
Jan 16, 2018: European Patent Granted for Bone Marrow Edema Lesions
Nov 23, 2017: Paradigm’s Two Arthritis Phase 2 Clinical Trials on Schedule
Nov 14, 2017: Paradigm Reports Successful Phase 2a BML/ACL Clinical Trial Results
Oct 30, 2017: First Participant Successfully Dosed in Phase 2b Clinical Trial for Osteoarthritis
Sep 19, 2017: Ethics Approval Received for Phase 2b Clinical Trial for Osteoarthritis
Sep 14, 2017: Paradigm Biopharmaceuticals: Significant momentum with Phase 2 Ross River Virus Clinical Trial
Sep 11, 2017: A Paradigm Shift in Treating Osteoarthritis Pain
Aug 09, 2017: Paradigm Successfully Doses First Participant in Phase 2 Ross River Virus Clinical Trial
Jul 10, 2017: Paradigm to Commence Phase 2 Ross River Virus Clinical Trial
May 16, 2017: Paradigm’s preclinical hay fever trial: peer-reviewed and published in leading scientific journal
Mar 23, 2017: Paradigm Biopharmaceuticals Announces Final participant treated in Phase 2 hay fever trial
Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River
Nov 22, 2016: Paradigm Phase 2 Hay Fever Trial gets Approval from Swedish MPA

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned:
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Takeda Pharmaceutical Co Ltd

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
• These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
• Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
• Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

• This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
• Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
• These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.
RECENT POSTS

What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10

Source URL: https://www.drugpipeline.net/global-markets-direct/collagenase-3-matrix-metalloproteinase-13-or-mmp13-or-ec-3424-pipeline-1

Links
[1] https://www.drugpipeline.net/region/global